Role of ADCs in HER2-Mutated NSCLC

Opinion
Video

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Related Videos
Video 14 - "Toxicity Profiles for DTC Guidelines Therapies"
Video 13 - "Understanding the Impact of COSMIC-311 and Sequencing in DTC"
Stephen V. Liu, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Manmeet Singh Ahluwalia, MD
Ibrahim Aldoss, MD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
A panel of 4 experts on colorectal cancer
Related Content
Margie Clapper, PhD, Co-Leader, Cancer Prevention and Control Research Program, Samuel M.V. Hamilton Chair in Cancer Prevention, Fox Chase Cancer Center

Fox Chase Cancer Center Researchers Show Estrogen Metabolites Contribute to Development of Lung Cancer Among People Who Never Smoked

May 2nd 2024
Article
Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

March 18th 2024
Podcast
Nicolas Girard, MD, PhD, of Curie-Montsouris Thorax Institute

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

April 26th 2024
Article
Diane M. Simeone, MD; Marwan G. Fakih, MD

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023
Podcast
Raj Singh, MD, of The Ohio State University Comprehensive Cancer Center––James

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024
Article
Mark Lanasa, MD, PhD

Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC

April 23rd 2024
Article